Corneal Collagen Cross-linking is NOT yet approved by the Food and Drug Administration (FDA) in the United States, but it has been successfully performed outside of the United States since 2007. It is currently performed in the U.S. as either part of an FDA trial or under an off-label status. Off-label refers to a procedure or device that is performed at the discretion of the surgeon and with the full consent of the patient, including a comprehensive discussion of risks, benefits, and alternatives to the proposed treatment.
Corneal Cross-linking is a relatively painless procedure that is performed to slow or stop the progression of Keratoconus. It uses special eye drops called Riboflavin and an advanced form of UV light to strengthen the bonds within the cornea. It does not cure Keratoconus. Cross-linking works to halt progrssion to prevent the cornea from becoming more irregular. Many patients will utilize other options for improving vision after Cross-linking, such as RGP lenses or Intacs®.